Company intelligence / Profile preview
Halo Biosciences
Palo Alto, California, United Stateshalobiosciences.com ↗
- Ownership
- Private
- Employees
- ~15
- Development stage
- Other
01
Overview
Halo Biosciences is developing first-in-class therapies that target the extracellular matrix by inhibiting hyaluronan synthesis. Their lead program is in clinical trials for pulmonary hypertension. Preclinical and early clinical data suggest their approach may significantly mitigate disease progression by reducing HA levels in affected tissues. Results from their initial clinical trial were expected in late 2023.[2]
- Therapeutic areas
- PulmonologyCardiovascular
- Modalities
- Small molecule inhibitors (specifically targeting hyaluronan synthesis)[2]
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Stanford University (intellectual property/licensing and scientific collaboration)[2]
Beyond the preview
Go deeper on Halo Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Halo Biosciences.